Men who have sex with men more often chose daily than event-driven use of pre-exposure prophylaxis: baseline analysis of a demonstration study in Amsterdam. by Hoornenborg, Elske et al.
RESEARCH ARTICLE
Men who have sex with men more often chose daily than
event-driven use of pre-exposure prophylaxis: baseline analysis
of a demonstration study in Amsterdam
Elske Hoornenborg1,2,* , Roel CA Achterbergh2,*, Maarten F Schim van der Loeff1,3, Udi Davidovich1,3,
Jannie J van der Helm1, Arjan Hogewoning2,4, Yvonne THP van Duijnhoven5, Gerard JB Sonder6,
Henry JC de Vries2,4,7,**, and Maria Prins1,3,** on behalf of the Amsterdam PrEP Project team in the HIV
Transmission Elimination AMsterdam Initiative
Corresponding author: Elske Hoornenborg, Nieuwe Achtergracht 100, 1018WT Amsterdam. Tel: +31 20 5555193. (ehoornenborg@ggd.amsterdam.nl)
*Both authors contributed equally to this article.
**Both authors contributed equally to this article.
Abstract
Introduction: The Amsterdam PrEP project is a prospective, open-label demonstration study at a large sexually transmitted
infection (STI) clinic. We examined the uptake of PrEP; the baseline characteristics of men who have sex with men (MSM) and
transgender persons initiating PrEP; their choices of daily versus event-driven PrEP and the determinants of these choices.
Methods: From August 2015 through May 2016, enrolment took place at the STI clinic of the Public Health Service of Ams-
terdam, the Netherlands. MSM or transgender persons were eligible if they had at least one risk factor for HIV infection
within the preceding six months. Participants were offered a choice between daily or event-driven use of tenofovir/emtric-
itabine. Baseline data were analysed using descriptive statistics and multivariable analysis was employed to determine variables
associated with daily versus event-driven PrEP.
Results: Online applications were submitted by 870 persons, of whom 587 were invited for a screening visit. Of them, 415
were screened for eligibility and 376 initiated PrEP. One quarter (103/376, 27%) chose event-driven PrEP. Prevalence of bac-
terial STI was 19.0% and mean condomless anal sex (CAS) episodes in the preceding three months were 11. In multivariable
analysis, older age (≥45 vs. ≤34, aOR 2.1, 95% CI 1.2 to 3.9), being involved in a steady relationship (aOR 1.7, 95% CI 1.0 to
2.7), no other daily medication use (aOR 0.6, 95% CI 0.3 to 0.9), and fewer episodes of CAS (per log increase aOR 0.7, 95%
CI 0.6 to 0.9) were determinants for choosing event-driven PrEP.
Discussion: PrEP programmes are becoming one of the more important intervention strategies with the goal of reducing inci-
dent HIV-infection and we were unable to accommodate many of the persons applying for this study. Offering a choice of dos-
ing regimen to PrEP users may enable further personalization of HIV prevention strategies and enhance up-take, adherence
and cost-effectiveness.
Conclusions: The majority of participants preferred daily versus event-driven use. Within this majority, a high number of CAS
episodes before PrEP initiation was reported and we observed a high prevalence of STI. Determinants of choosing event-
driven PrEP were older age, fewer CAS episodes, no other daily medication use, and involved in a steady relationship.
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1 | INTRODUCTION
In the Netherlands, men who have sex with men (MSM)
accounted for 65% of new HIV diagnoses in 2015 and HIV
incidence has not been markedly declining [1]. These findings
indicate the urgent need for new methods of HIV prevention.
The use of daily oral tenofovir disoproxil fumarate combined
with emtricitabine (TDF/FTC) as pre-exposure prophylaxis
(PrEP) effectively protects MSM against HIV infection [2]. The
Ipergay study showed comparable efficacy in MSM when
using non-daily event-driven dosing of PrEP (i.e. taking PrEP
before and after sexual contact) [3,4].While daily PrEP use for
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at-risk populations has been included in several guidelines (e.g.
World Health Organization and U.S. Centers for Diseases
Control and Prevention) [5,6], event-driven PrEP use has been
recommended in French guidelines and the most recent Euro-
pean Aids Clinical Society guidelines [7,8].
Issues that impede PrEP implementation in high-income
countries include uncertainty about the numbers and charac-
teristics of PrEP users, as well as costs related to its use
[9,10]. Event-driven use could improve cost-effectiveness
since fewer pills are required [11,12]. For client-centred and
cost-effective implementation, more information is needed on
the uptake of both daily and event-driven dosing regimens in
real-life settings and on the determinants of choosing between
these regimens.
We started the Amsterdam PrEP (AMPrEP) demonstration
project with the aim of assessing uptake of daily and event-dri-
ven PrEP, at the participant’s discretion, among HIV-negative
MSM and transgender persons at increased risk for HIV infec-
tion. This project was part of a comprehensive HIV-reduction
package offered at a large STI clinic. We assessed interest in
PrEP use by reporting the number of study applicants during
the study application period and evaluated baseline characteris-
tics including STI prevalence and preference for daily versus
event-driven PrEP use. In addition, we examined the predomi-
nant self-reported motives for PrEP use and choice of regimen,
and analysed determinants for choosing event-driven PrEP use.
2 | METHODS
2.1 | Application procedures and study site
The AMPrEP project, a prospective, longitudinal, open-label
demonstration study, began in June 2015. A press release
announced the start of the study and the number of available
spots (n=370), followed by large-scale media attention at the
local and national level. We reached out to transgender people
through their community organizations and via the centre for
prostitution and health, which offers information, advice and
support to sex workers including transgender persons. How-
ever, we did not launch a media campaign to recruit partici-
pants. The main inclusion criteria were published online and
people interested in participating applied using a web-based
form. On this form, we asked them to select all applicable
inclusion criteria. Since a high number of interested people
was expected and we wanted to allow ample time for individu-
als to express their interest in participation, we decided not to
include individuals on a first-come, first-serve basis, but
instead opted for a four-week application period (initial appli-
cation period). All applicants then received a randomly-
assigned rank number for a subsequent screening visit. No
stratified sampling of at-risk subgroups (e.g. based on sexual
behaviour characteristics, for young MSM, or transgender per-
sons) was employed. During the first screening visit and prior
to any assessments, applicants provided written informed con-
sent to participate in the study. Visits took place from 3
August 2015 to 30 May 2016 at the STI outpatient clinic of
the Public Health Service of Amsterdam (GGD). This is the lar-
gest STI clinic in the Netherlands, performing about 45,000
consultations yearly; 38% of clients are MSM. In 2017, we
diagnosed 92 HIV infections, 77 of these were MSM.
The study was approved by the ethics board of the Aca-
demic Medical Center, Amsterdam, the Netherlands
(NL49504.018.14). The AMPrEP project is part of the HIV
Transmission Elimination AMsterdam (H-TEAM) initiative, a
multidisciplinary and integrative approach to stop the urban
epidemic (Hteam.nl). The AMPrEP study was registered at the
online Dutch trial registry (registration number NTR5411)
and the protocol is available online [13].
2.2 | Eligibility criteria
HIV-negative MSM and transgender persons (male-to-female
and female-to-male) who have sex with men were eligible if
they were at least 18 years of age and had one or more of
the following risk factors for HIV infection within six months
prior to the screening visit: condomless anal sex (CAS) with
casual partners, at least one bacterial STI (i.e. syphilis, rectal
or urethral chlamydia or gonorrhoea), use of post-exposure
prophylaxis (PEP) after a sexual risk incident, or an HIV-posi-
tive sexual partner with a detectable viral load. We excluded
people if they tested positive for hepatitis B surface antigen
(HBsAg); had creatinine clearance rate according to the Cock-
roft-Gault equation less than 60 mL/minute [14]; had more
than trace protein in urine, or had other contra-indications for
TDF/FTC use (see protocol [13]). In case of symptoms or
signs suggestive of acute HIV infection, we performed rapid
point-of-care HIV RNA testing.
2.3 | PrEP dosing regimen
Participants were proposed a choice of free-of-charge daily
or event-driven PrEP (TDF/FTC) use. Also, no costs were
incurred on the participants for renal function and STI test-
ing. Daily use consisted of one pill every day and event-dri-
ven use two tablets taken between 24 hours and 2 hours
before CAS, followed by one tablet every 24 hours up to
48 hours after the last episode of sexual intercourse [3]. In
the decision-making process, we used shared and informed
decision making, (i.e. we explained both PrEP regimens and
answered questions), thus providing the necessary informa-
tion for participants to select the option most-adapted to
their lifestyle. No advice was given on the suitability of their
decision of PrEP regimen. In addition, we informed partici-
pants that switching PrEP regimen was allowed at each
subsequent study visit.
2.4 | Study visits
At the screening visit, eligibility criteria were verified. Urine,
blood and pharyngeal/anal samples were taken to test for STI,
hepatitis B virus (HBV), HIV, serum creatinine and urine pro-
tein (Figure 1). One to four weeks later at PrEP initiation, we
verified that all diagnosed STI had been treated according to
clinic protocols, and if not we provided immediate treatment;
eligibility criteria were confirmed, a self-administered ques-
tionnaire was completed, and blood was taken to test for HIV,
hepatitis C virus (HCV) and HBV infections. Participants were
asked to return for follow-up visits one month after the PrEP
initiation visit and every three months thereafter. They will be
provided with PrEP until June 2018.
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2.5 | Diagnostic testing
We performed HIV and STI testing according to routine STI
clinic protocols. This included HIV antigen and antibody testing
(LIAISON XL Murex HIV Ag/Ab, Diasorin, Saluggia, Italy) with
immunoblot confirmation (INNO_LIPA HIV I/II Score, Fujirebio,
Ghent, Belgium), and serology testing for syphilis (LIAISON
Treponema Screen, Diasorin). If indicated, direct microscopy
(dark-field or Gram-stained smear) was performed for samples
taken from rectal or urethral ulcers or discharge to detect the
presence of Neisseria gonorrhoeae or Treponema pallidum.
Nucleic amplification testing for Chlamydia trachomatis and
Neisseria gonorrhoeae (Aptima combo 2, Hologic Gen-Probe
Inc., San Diego, USA) was performed on urine, anal and pha-
ryngeal swabs. Samples from participants without a history of
HBV vaccination were screened for anti-Hepatitis B core and
anti-Hepatitis B surface antibodies (LIAISON Anti-HBc and
anti-HBs II, Diasorin) and, if negative, participants were
offered HBV vaccination.
In addition to the routine STI clinic protocol, blood taken at
the PrEP initiation visit was tested for anti-HCV antibodies
(Architect anti-HCV, Abbott Laboratories, Wiesbaden, Ger-
many) with immunoblot confirmation (INNO-LIPA HCV Score,
Fujirebio, Ghent, Belgium) as was previously described [15].
Participants were also tested for the presence of HIV RNA,
HCV RNA and HBV DNA in pools of six plasma samples
(COBAS Taqscreen MPX Test v2.0, Roche Diagnostics, Man-
nheim, Germany). Samples in HBV DNA-positive pools were
tested for HBsAg (Architect HBsAg, Abbott Laboratories,
Wiesbaden, Germany), and HBsAg-positive samples were indi-
vidually tested for HBV DNA (CAP-CTM HBV test v2.0,
Roche Diagnostics, Mannheim, Germany). None of the pools
tested positive for HIV-1/2 RNA.
2.6 | Measurements
2.6.1 | Participant characteristics and risk behaviour
At the PrEP initiation visit, participants completed a self-admi-
nistered questionnaire on risk behaviour over the past three
months, socio-demographic characteristics (e.g. postal code, sex-
ual preference, education, employment, income and living situa-
tion), and their main reason for participating in the AMPrEP
project (from a list of 10 predefined options). Questions were
asked on concern of acquiring HIV using a Likert scale from one
(very concerned) to seven (not concerned at all). Educational
level was divided into low (primary school and lower secondary
vocational education), medium (intermediate and higher sec-
ondary general education, senior secondary vocational and pre-
university education) or high (higher professional or university
education). Regarding sexual behaviour, participants were asked
about number and type (steady, known casual, or anonymous) of
sexual partners, the number and type (insertive or receptive) of
anal sex episodes, and condom use. Using lay terms, questions
were asked on substance use, both in general and around the
time of sex, and whether they had injected any drugs. Chemsex
Figure 1. Overview of the numbers of applications, people screened and starting daily and event-driven PrEP in AMPrEP. Baseline charac-
teristics were obtained at the screening or PrEP initiation visit. (1) From 22 June to 20 July 2015. (2) From 20 July 2015 to 12 April 2016.
(3) Screening and PrEP initiation took place from August 2015 until June 2016. (4) At the screening visit, we obtained informed consent and
took samples to test for sexually transmitted infections, including HIV and hepatitis B virus infection, and kidney function. (5) At the PrEP
initiation visit, we took samples for pooled HIV, hepatitis B and hepatitis C virus testing; we performed a semi-structured interview on par-
ticipants’ main reason to start PrEP and for choosing daily or event-based PrEP. We also collected self-reported questionnaire data.
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was defined as using gamma-hydroxybutyrate (GHB)/gamma-
butyrolactone (GBL), mephedrone or crystallized metham-
phetamine around the time of sex [16]. Finally, participants were
asked if they routinely used medication and pharmaceutical
interactions with TDF/FTC were checked.
2.6.2 | Other measurements at PrEP initiation
Participants were asked the most important reason to partici-
pate in the AMPrEP project and to complete the Mental Health
Inventory screening test (MHI-5), Alcohol Use Disorders Identi-
fication Test (AUDIT), Drug Use Disorders Identification Test
(DUDIT), and sexual compulsivity scale (SCS) [17]. The following
score cutoffs were used to identify specific problems: 60 for
MHI-5 (i.e. lower than 60 suggests an anxiety or depressive
mood disorder) [18,19], eight for AUDIT (i.e. eight and higher
suggests harmful alcohol use) [20], eight for DUDIT (i.e. eight
and higher suggests drug-related problems) [21] and 24 for
SCS (i.e. 24 and higher suggests a greater impact of sexual
thoughts on daily functioning and an inability to control sexual
thoughts or behaviours) [22,23].
Semi-structured interviews were used to identify the two
most important motives for choosing daily versus event-driven
PrEP at the PrEP initiation visit.
2.7 | Statistical analyses
First, we described the number of applicants, number
screened and number initiating PrEP. Second, we reported the
socio-demographic characteristics, risk behaviour, STI diag-
noses, choice of PrEP dosing regimen and motives for partici-
pation and choice. Third, we compared characteristics
between participants who chose daily PrEP compared to
event-driven PrEP using Chi-squared tests for categorical data
and student t-test or rank sum tests for continuous data.
Fourth, variables associated at p < 0.15 in univariable analysis
were included in a multivariable logistic regression model
while forcing inclusion of age as a covariable. In case of
collinearity between variables (e.g. number of anal sex part-
ners and number of anal sex episodes), only one of the colli-
near variables was included. Number of CAS episodes was
natural log transformed. Using a backward step-wise proce-
dure, we retained variables with a p < 0.05 (according to the
likelihood ratio test) in the final multivariable model. All analy-
ses were performed using STATA Intercooled 13.1 (STATA
Corporation, College Station, TX, USA).
3 | RESULTS
3.1 | Individuals applying and assessed for
participation
In total, 870 online applications were submitted from June
2015 to April 2016: 535 during the 4-week initial application
period and 335 in the nine months thereafter (Figure 1).
Between August 2015 and June 2016, 587 of 870 persons
were invited for a screening visit, of whom 415 (77.6%)
attended their visit. Of them, 376 (90.6%) initiated PrEP.
Twenty-three people did not meet any of the four risk factors
for HIV infection (see methods), and exclusion criteria disquali-
fied four people from inclusion (Figure 1).
3.2 | Socio-demographic characteristics and STI
prevalence
Two of the 376 participants self-identified as male-to-female
transgender persons and 374 as MSM (Table 1). Most of the
participants were white (85.1%) and had a high educational
level (76.1%). The median age was 39 years [interquartile
range (IQR), 32 to 48].
At PrEP initiation, 71 of 376 (19.0%) were diagnosed with a
bacterial STI. Overall, 42 (11.2%) cases of anal gonorrhoea or
chlamydia and 6 (1.6%) cases of syphilis were diagnosed. More-
over, 18 (4.8%) were positive for anti-HCV (n=17) and/or HCV
RNA (n=15). Of 228 participants who had tested at the STI
clinic within the preceding year, 103 (45.2%) had been diag-
nosed with a bacterial STI. Two people initiating daily PrEP
tested HBsAg-positive, but were enrolled despite this exclusion
criterion. One had been using event-driven PrEP, unmonitored
and obtained elsewhere, while the second was mistakenly
included. We referred both to specialist care to have their
HBV infection monitored. Furthermore, we allowed continua-
tion of study participation and advised to use PrEP daily to pre-
vent hepatic flares when PrEP is interrupted.
3.3 | Sexual risk behaviour, drug use and other
measurements
Characteristics of risk behaviour and drug use in the three
months prior to PrEP initiation are described in Table 1. The
median number of anal sex partners in the three months before
PrEP initiation was 15 [IQR 6 to 30] and the median number of
CAS episodes was 11 (IQR 4 to 23). Of all participants, 282
(75.0%) reported receptive CAS, and 203 (54.0%) reported at
least ten CAS episodes in the preceding three months.
Of all participants, 156 (42.0%) reported chemsex and 15
(4.0%) reported injecting drug use in the preceding three
months. More than one third (35.7%) scored eight or higher
on DUDIT and 28.0% scored eight or higher on AUDIT, sug-
gesting drug and alcohol use disorder respectively. According
to the MHI-5, 20.7% scored below 60, suggesting a depres-
sive mood and/or anxiety disorder.
3.4 | Preferences for daily versus event-driven PrEP
use
Of 376 persons who initiated PrEP, 273 (72.6%) opted for
daily use. Median age of daily PrEP users was 38 years [IQR
30 to 47], 111 (41.1%) were involved in a steady relationship
and 86 (31.5%) were living with their partner. Daily PrEP
users reported a median number of 15 [IQR 8 to 30] anal sex
partners in the preceding three months.
Those who opted for event-driven PrEP had a median age
of 44 years [IQR 35 to 51], 53 (52.0%) were involved in a
steady relationship and 35 (34.0%) were living with their part-
ner. In the preceding three months, they reported a median
number of 10 [IQR 5 to 25] anal sex partners.
3.5 | Motives for participation and choice of PrEP
regimen
The main reasons for participation were to have better pro-
tection against HIV (n=184, 49.1%) or to worry less about
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Table 1. Baseline characteristics of daily and event-driven PrEP users in AMPrEP 2015 to 2016
Total (N=376)
Event driven PrEP
users (N=103)
Daily PrEP
users (N=273)
p valueN %a n %a n %a
Demographic characteristics
Age (years)
Median [IQR] 39 [32 to 48] 44 [35 to 51] 38 [30 to 47] <0.001
≤34 126 33.5 25 24.3 101 36.9 0.016
35 to 44 112 29.8 29 28.2 83 30.4
≥45 138 36.7 49 47.6 89 32.6
Gender identity 0.473
Male 374 99.5 102 99.0 272 99.6
Transgender woman 2 0.5 1 1.0 1 0.4
Self-declared ethnicityb 0.160
White 315 85.1 92 89.3 223 83.5
Non-white 55 14.9 11 10.7 44 16.5
Country of origin 0.811
Netherlands 295 78.5 82 79.6 213 78.0
Other high-income country 39 10.4 9 8.7 30 11.0
Other 42 11.2 12 11.7 30 11.0
Residence 0.155
Amsterdam 230 61.2 69 67.0 161 59.0
Other 146 38.8 34 33.0 112 41.0
Educational level 0.071
Low and middle 90 23.9 18 17.5 72 26.4
High 286 76.1 85 82.5 201 73.6
Employmentd 0.071
Yes 290 77.1 80 77.7 210 78.1
Student 31 8.2 3 2.9 28 10.4
No, volunteer 7 1.9 3 2.9 4 1.5
No, unable due to disability 6 1.6 1 1.0 5 1.9
No, retired 19 5.1 8 7.8 11 4.1
No, unemployed 19 5.1 8 7.8 11 4.1
Monthly net income levele 0.423
Low (≤€1700) 99 27.7 25 25.0 74 28.8
Middle (€1701 to €2950) 151 42.3 40 40.0 111 43.2
High (>€2950) 107 30.0 35 35.0 72 28.0
Current steady relationshipd 0.060
No 208 55.9 49 48.0 159 58.9
Yes 164 44.1 53 52.0 111 41.1
Living situation 0.029
Alone 200 53.9 61 59.2 139 50.9
With partner 121 32.2 35 34.0 86 31.5
With others 55 14.6 7 6.8 48 17.6
Sexual behaviour characteristics
Sexual preferencec 0.890
Exclusively homosexual 296 78.7 81 79.4 215 78.8
Not exclusively homosexual 79 21.0 21 20.6 58 21.3
Concerned about acquiring HIV (scale 1–7)f
Median [IQR] 3 [2 to 4] 3 [2 to 4] 3 [2 to 4] 0.843
Eligibility criteriag
Sexually transmitted infectionh 135 35.9 29 28.2 106 38.8 0.054
Post-exposure prophylaxis used 27 7.2 4 3.9 23 8.4 0.128
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Table 1. (Continued)
Total (N=376)
Event driven PrEP
users (N=103)
Daily PrEP
users (N=273)
p valueN %a n %a n %a
CAS with casual partner(s) 359 95.5 100 97.1 259 94.9 0.356
HIV-positive partner with a
detectable viral load
9 2.4 1 1.0 8 2.9 0.268
Number of eligibility criteria 0.037
1 235 62.5 75 72.8 159 58.5
2 127 33.8 25 24.3 102 37.5
3 14 3.7 3 2.9 11 4.0
STI diagnosed at PrEP initiation
Anorectal chlamydiai 19 5.1 4 3.9 15 5.5 0.516
Chlamydiai (any site) 32 8.6 6 5.8 26 9.6 0.244
Anorectal gonorrhoeai 25 6.7 7 6.8 18 6.6 0.958
Gonorrhoeai (any site) 36 9.6 11 10.7 25 9.2 0.670
Syphilis (stage 1 or 2)i 6 1.6 1 1.0 5 1.9 0.548
Hepatitis C antibody or RNAc 18 4.8 4 3.9 14 5.2 0.609
Hepatitis B surface antigen 2 0.5 0 2 0.7
Anal chlamydia or gonorrhoeai 42 11.2 11 10.7 31 11.4 0.835
Any bacterial STIi, j (any site) 71 19.0 18 17.5 53 19.6 0.647
STI diagnosed at clinic preceding PrEP initiation
Any bacterial STI preceding
yearj, k (any site)
103 45.2 23 36.0 80 48.8 0.096
Any bacterial STI preceding three
yearsj, l (any site)
155 61.5 41 58.6 114 62.6 0.586
Number of anal sex partners (3M)
Median [IQR] 15 [6 to 30] 10 [5 to 25] 15 [8 to 30] 0.015
0 to 1 8 2.1 4 3.9 4 1.5 0.116
2 to 5 67 17.8 23 22.3 44 16.1
6 to 9 52 13.8 16 15.5 36 13.2
10 to 24 116 30.9 33 32.0 83 30.4
≥25 133 35.4 27 26.2 106 38.8
Number of condomless anal sex episodes (3M)
Median [IQR] 11 [4 to 23] 8 [2 to 17] 12 [5 to 25] 0.008
0 to 1 51 13.6 22 21.4 29 10.6 0.061
2 to 5 73 19.4 20 19.4 53 19.4
6 to 9 49 13.0 15 14.6 34 12.5
10 to 24 115 30.6 27 26.2 88 32.2
≥25 88 23.4 19 18.5 69 25.3
Position during condomless anal sex (3M) 0.053
None 29 7.7 14 13.6 15 5.5
Insertive only 65 17.3 16 15.5 49 18.0
Receptive only 63 16.8 19 18.5 44 16.1
Both insertive and receptive 219 58.2 54 52.4 165 60.4
Most high-risk type partner (3M)c 0.238
Anonymous partner 344 92.0 89 88.1 255 93.4
Known casual/ex steady partner 27 7.2 11 10.9 16 5.9
Steady partner 3 0.8 1 1.0 2 0.7
Mental health characteristics and drug use
Depressive or anxiety symptoms 0.641
MHI-5 score <60m (symptoms) 78 20.7 23 22.3 55 20.2
MHI-5 score ≥60n (no symptoms) 298 79.3 80 77.7 218 79.9
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contracting HIV (n=98, 26.1%) (Figure 2A). The two main rea-
sons for PrEP regimen choice were daily PrEP – “it is easier to
use” and “it is difficult to predict when I will have sex;” event-
driven PrEP – “I am able to predict sex” and “I am not often at
risk” (Figure 2B and C).
3.6 | Determinants for choosing event-driven PrEP
use
In univariable analyses, older age was positively associated
with choosing event-driven PrEP, whereas persons with
higher numbers of anal sex partners and CAS episodes and
more eligibility criteria were less likely to choose event-dri-
ven PrEP (Tables 1 and 2). Several other factors, including
educational level and a higher score on the screening tool
for drug disorder were not associated with choice of PrEP
regimen. In multivariable analyses, older age (≥45 vs.≤34,
adjusted odds ratio (aOR) 2.1, 95% CI 1.2 to 3.9) and being
involved in a steady relationship (aOR 1.7, 95% CI 1.0 to
2.7) were positively associated with event-driven PrEP; daily
medication use (aOR 0.6, 95% CI 0.3 to 0.9) and more CAS
episodes in the preceding three months (per log increase
Table 1. (Continued)
Total (N=376)
Event driven PrEP
users (N=103)
Daily PrEP
users (N=273)
p valueN %a n %a n %a
Alcohol use disorder identification
test (AUDIT)o
0.878
Score <8p (no indication) 267 72.0 74 72.6 193 71.8
Score ≥8q (indication) 104 28.0 28 27.5 76 28.3
Drug use disorders identification
test (DUDIT)r
0.119
Score <8s (no indication) 236 64.3 71 69.6 165 60.9
Score ≥8t (indication) 137 35.7 31 30.4 106 39.1
Sexual compulsivity scalec 0.394
Score <24u (no indication) 291 77.6 83 80.6 208 76.5
Score ≥24v (indication) 84 22.4 20 19.4 64 23.5
Alcohol use during sex (3M)w 235 63.3 62 61.4 173 64.1 0.632
Drug use during sex (3M)
Amphetaminew 68 18.3 18 17.8 50 18.5 0.877
Cannabisx 104 28.2 26 25.7 78 29.1 0.522
Cocaineb 98 26.5 27 26.7 71 26.4 0.948
Erectile dysfunction drugsb 260 70.5 67 66.3 193 72.0 0.286
GHB/GBLw 146 39.4 39 38.6 107 39.6 0.859
Ketaminex 66 17.9 18 18.0 48 17.8 0.972
Methamphetaminew 34 9.2 7 7.0 27 10.0 0.380
Mephedronew 31 8.2 11 11.0 20 7.4 0.264
Nitritesw 259 69.8 66 65.4 193 71.5 0.252
XTC/MDMAb 161 43.5 40 40 121 44.8 0.407
Othery 36 10.1 10 10.4 26 10.0 0.908
Any drugs during sex (3M)z 330 89.7 89 89.0 241 89.9 0.795
Chemsex (3M)* 156 42.0 44 43.6 112 41.5 0.718
Injecting drug use (3M)w 15 4.0 3 3.0 12 4.4 0.521
Daily medicine use 114 30.3 25 24.3 89 32.6 0.117
AMPrEP, Amsterdam PrEP project; PrEP, pre-exposure prophylaxis; IQR, interquartile range; STI, sexually transmitted infection; MHI5, Mental
Health Inventory 5; RNA, Ribonucleic acid; CAS, condomless anal sex; GHB, c-hydroxybutyrate; GBL, c-Butyrolactone; XTC, ecstasy; MDMA, 3,4-
Methylenedioxymethamphetamine.
aPercentages may not total 100 because of rounding, percentage is within group of PrEP users; b6 missing; c1 missing; d4 missing; e19 missing/did
not want to say; f1 very concerned, 7 not concerned at all; gIn the previous 6 months, self reported risk factors; hSTI include only rectal, urethral
chlamydia/gonorrhea or syphilis; i2 missing; jChlamydia, gonorrhoea or syphilis diagnosed at STI clinic Amsterdam; k148 missing; l124 missing;
mNo indication of an anxiety or depressive mood disorder; nPossible indication of an anxiety or depressive mood disorder; o5 missing; p1 No indi-
cation of alcohol use disorder; qIndication of possible alcohol use disorder; r3 missing; sNo indication of drug use disorder; tIndication of possible
drug use disorder; uNo indication of sexual compulsivity; vIndication of possible sexual compulsivity; w5 missing; x7 missing; y20 missing; others
include: opiates (8), mushrooms (1), methylphenidate (8), testosterone (7), Methoxetamine (MXE, 2), 4-broom-2,5-dimethoxyfenethylamine (2CB,
5), Lysergic acid diethylamide (LSD, 3), 4-Fluoroamphetamine (4FA, 15), 4-Methylethcathinone (4-MEC, 1); zother than alcohol, 8 missing; *defined
as the use of GHB/GBL or Methamphetamine or Mephedrone during sex; 3M: in the previous 3 months.
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aOR 0.7, 95% CI 0.6 to 0.9) were negatively associated with
event-driven PrEP.
4 | DISCUSSION
In the Amsterdam PrEP project, the demand for PrEP among
MSM largely exceeded capacity. The majority of the partici-
pants in this Dutch demonstration project preferred daily ver-
sus event-driven use. Within this majority, a high number of
CAS episodes before PrEP initiation was reported and a high
prevalence of STI, including HCV was observed. Furthermore,
42% reported engaging in chemsex. Determinants of choosing
event-driven PrEP were older age, fewer CAS episodes in the
preceding three months, no other daily medication use, and
being in a steady relationship.
To the best of our knowledge, we are the first to report on
the preferences between daily and event-driven PrEP among
MSM and the reasons for such preferences. Although most
people opted for daily use, about one quarter preferred
event-driven use. People who opted for event-driven PrEP
reported fewer CAS episodes and thus would require PrEP
less often for protection; they were less likely to take daily
medication whereby daily PrEP could be conveniently inte-
grated. Providing individuals a choice between daily or event-
driven PrEP would appear to enable further personalization of
their HIV prevention strategy and could accompany increased
adherence and resulting protection. In addition, as event-dri-
ven users take fewer PrEP pills, offering this choice has the
potential to reduce cost at the individual and population level
alike, and improve cost-effectiveness [11,12]. In a PrEP rollout
study in France, uptake of daily PrEP is lower than in our pro-
ject: 41% of individuals preferred daily PrEP and 59% event-
driven PrEP [4]. The difference in regimen preference
between the French study and our own might reflect the fact
that French providers and MSM were more familiar with
event-driven dosing from the randomized-controlled trial Iper-
gay in France [3].
The demand for PrEP was reflected by the large number of
submitted applications to participate in AMPrEP over a short
time period. Nevertheless, we clearly stated to participants
that late applicants were unlikely to be enrolled due to limited
capacity. Potential applicants interested in PrEP could have
perceived their chance of inclusion as low and thus were
(A)
(B) (C)
Figure 2. (A) Main motives for joining the Amsterdam PrEP project (one motive per participant); (B). Main motives (two per participant) for
choosing daily PrEP; (C). Main motives (two per participant) for choosing event-driven PrEP. Proportions of all participants who reported a
first/second reason on the x-axis and absolute numbers behind the bars.
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discouraged from participating, implying that the number of
those actually interested in initiating PrEP in Amsterdam are
higher than the number of applicants to the AMPrEP project.
Currently, few data on intention to use PrEP in the Nether-
lands have been published [24,25] and only crude estimates
of the number of MSM willing to take PrEP are available
[26,27].
The participants initiating PrEP in this study were indeed at
substantial risk for HIV infection, as shown by a high median
number of CAS episodes and high STI prevalence. The propor-
tion with a bacterial STI (19.0%) at PrEP initiation
corresponded to other PrEP cohorts (15.9% to 28.8%) [3,28].
However, the prevalence of HCV infection was higher in our
study [3,15,29], indicating that STI testing strategies should
include HCV among HIV-negative MSM initiating PrEP.
The proportion of men reporting chemsex in the three
months before PrEP initiation is high and in line with two
other European PrEP cohorts [3,19] and with studies in the
larger MSM community [30,31]. Moreover, in our study, a
large proportion scored low on MHI-5 or high on the DUDIT,
AUDIT, or SCS screening tools, indicating risk for anxiety or
depressive mood disorder, alcohol and drug use disorder, or
Table 2. Univariable and multivariable analysis of determinants for choosing event-driven PrEP among 376 participants in AMPrEP
2015 to 2016
n choosing
event-driven/totala (%)
Univariable
OR [95% CI] Multivariableb OR [95% CI] p value
Age (years) 0.027
≤34 25/126 (19.8) 1 1
35 to 44 29/112 (25.9) 1.4 [0.8 to 2.6] 1.3 [0.7 to 2.4]
≥45 49/138 (35.5) 2.2 [1.3 to 3.9] 2.1 [1.2 to 3.9]
Educational level
Low and middle 18/90 (20.0) 1
High 85/286 (29.7) 1.7 [1.0 to 3.0]
Employment/studentc
Yes 83/238 (25.9) 0.5 [0.3 to 1.0]
No 20/31 (39.2)
Current steady relationshipc 0.045
No 49/208 (23.6) 1 1
Yes 53/164 (32.3) 1.5 [1.0 to 2.4] 1.7 [1.0 to 2.7]
Living situationd
Alone 61/200 (30.5) 1
With partner 35/121 (28.9) 0.9 [0.6 to 1.5]
With others 7/55 (12.7) 0.3 [0.1 to 0.8]
Number of eligibility criteriae
1 75/234 (31.9) 1
2 or 3 28/141 (19.9) 0.5 [0.3 to 0.9]
Ln of number of anal sex partnersd
Per 1 increase 0.8 [0.6 to 1.0]
Ln of number of condomless anal sex episodes 0.005
Per 1 increase 0.8 [0.6 to 1.0] 0.7 [0.6 to 0.9]
Position during condomless anal sex
None 14/29 (48.3) 1
Top only 16/65 (24.6) 0.3 [0.1 to 0.9]
Bottom only 19/63 (30.2) 0.5 [0.2 to 1.1]
Versatile 54/219 (24.7) 0.4 [0.2 to 0.8]
Drug use disorder identification test (DUDIT)f
Score <8 (no indication) 71/236 (30.8) 1
Score ≥8 (indication) 31/137 (22.6) 0.7 [0.4 to 1.1]
Daily medicine use 0.041
No other daily medicine use 78/262 (29.8) 1 1
Other daily medicine use 25/114 (21.9) 0.7 [0.4 to 1.1] 0.6 [0.3 to 0.9]
PrEP, pre-exposure prophylaxis; AMPrEP, Amsterdam PrEP project; DUDIT, Drug Use Disorders Identification Test.
aPercentages may not total 100 because of rounding, percentage is within variable group; bmultivariable model is based on 372 participants;
c4 missing; dnot included in multivariable model due to collinearity; e1 missing; f2 missing.
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sexual compulsivity. Even though sexual minorities are known
to have more mental health problems (e.g. alcohol dependence
5.4% in heterosexuals compared with 10.4% in non-heterosex-
uals) [32], these scores are alarmingly high. Addressing and, if
indicated, referral for substance use, sexual compulsivity and
mental health should be integrated into PrEP programmes,
and the quarterly visits offer ample opportunity to do so.
Despite efforts to inform all PrEP-eligible populations, our
study included very few transgender persons, as was the case
in other PrEP studies from Europe and elsewhere
[3,19,33,34]. To increase their inclusion, future studies will
require additional and specifically-tailored PrEP campaigns and
programmes based on research identifying the specific needs
of transgender people at risk for HIV infection (e.g. providing
PrEP at gender-affirming care facilities) [35,36].
One limitation of our study is that, despite the project being
conducted in an STI clinic offering routine sexual healthcare,
choices for daily and event-driven PrEP may not reflect those
in the population at large. It should be mentioned that PrEP
was offered free-of-charge, which is currently not the case in
most countries. More people might opt for event-driven PrEP
under the premise that future practice would require pay-
ment. Furthermore, our project is the first to offer access to a
free-of-charge PrEP programme in the Netherlands and as a
result, we may have attracted a higher number of early
adopters who may not be representative of the wider MSM
community.
The major strength of this study is the knowledge gener-
ated on PrEP use and choice of dosing regimens in a real-
world setting. So far, little data have been available, especially
in Europe. The STI clinic in Amsterdam represents an ideal
location for conducting this PrEP project given the frequent
previous STI testing among participants (Table 1). Our initially
high number of online applications provides further support
for implementation of PrEP at STI clinics.
In conclusion, we were unable to accommodate many of the
persons applying for this study in the Netherlands. Participants
were willing to start daily or event-driven PrEP as part of their
routine STI care. They were able to choose a dosing regimen
and the larger preference towards daily use was probably
related to their risk behaviour. Offering a choice of dosing regi-
men may enhance uptake, adherence, and cost-effectiveness.
The results of this study are important for policy makers, health
insurers, and healthcare professionals concerned with imple-
mentation of efficient and cost-effective PrEP programmes in
high-income countries. Until the availability of new interven-
tions, such as an HIV vaccine, PrEP programmes are becoming
one of the more important intervention strategies with the goal
of reducing incident HIV infection. Therefore, it is of importance
to provide the option between daily and event-driven PrEP for
all people at high risk of acquiring HIV.
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